Clinical Trial Update: Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of a vaccine immunotherapy for recurrent medulloblastoma and primitive neuroectodermal tumor has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medulloblastoma
• Primitive Neuroectodermal Tumor

Snippet

Sponsor: University of Florida | Conditions: Medulloblastoma, Neuroectodermal Tumor | Phase 2 | Status: COMPLETED | Results posted: 2022-02-07